ALOX5-mediated ferroptosis acts as a distinct cell death pathway upon oxidative stress in Huntington's disease
Genes & Development · 01.03.2023 · 37 (5-6) · 204-217
DOI: 10.1101/gad.350211.122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes & Development, online erschienen am 15.03.2023. Verfasst von Shujuan Song und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Cancer Genetics, Department of Pathology and Cell Biology, Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians an…. Hauptthemen laut MEDLINE: Ferroptosis, Huntington Disease. Die Arbeit wurde bisher 126-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, National Institutes of Health.
Abstract (Originalsprache)
Although it is well established that Huntington's disease (HD) is mainly caused by polyglutamine-expanded mutant huntingtin (mHTT), the molecular mechanism of mHTT-mediated actions is not fully understood. Here, we showed that expression of the N-terminal fragment containing the expanded polyglutamine (HTTQ94) of mHTT is able to promote both the ACSL4-dependent and the ACSL4-independent ferroptosis. Surprisingly, inactivation of the ACSL4-dependent ferroptosis fails to show any effect on the life span of Huntington's disease mice. Moreover, by using RNAi-mediated screening, we identified ALOX5 as a major factor required for the ACSL4-independent ferroptosis induced by HTTQ94. Although ALOX5 is not required for the ferroptotic responses triggered by common ferroptosis inducers such as erastin, loss of ALOX5 expression abolishes HTTQ94-mediated ferroptosis upon reactive oxygen species (ROS)-induced stress. Interestingly, ALOX5 is also required for HTTQ94-mediated ferroptosis in neuronal cells upon high levels of glutamate. Mechanistically, HTTQ94 activates ALOX5-mediated ferroptosis by stabilizing FLAP, an essential cofactor of ALOX5-mediated lipoxygenase activity. Notably, inactivation of the Alox5 gene abrogates the ferroptosis activity in the striatal neurons from the HD mice; more importantly, loss of ALOX5 significantly ameliorates the pathological phenotypes and extends the life spans of these HD mice. Taken together, these results demonstrate that ALOX5 is critical for mHTT-mediated ferroptosis and suggest that ALOX5 is a potential new target for Huntington's disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Cancer Genetics, Department of Pathology and Cell Biology, Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New Y…
- Department of Medical Genetics, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
- Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
- Department of Biological Sciences, Department of Chemistry, Columbia University, New York, New York 10027, USA.
ORCID-Profile: Wei Gu
Förderung
- NCI NIH HHS
- National Cancer Institute
- National Institutes of Health
- Herbert Irving Comprehensive Cancer Center
- NIH
- NCI
Zitieren
APA
Song, S., Su, Z., Kon, N., Chu, B., Li, H., Jiang, X., Luo, J., Stockwell, B. R., & Gu, W. (2023). ALOX5-mediated ferroptosis acts as a distinct cell death pathway upon oxidative stress in Huntington's disease. Genes & Development, 37(5-6), 204-217. https://doi.org/10.1101/gad.350211.122
Vancouver
Song S, Su Z, Kon N, Chu B, Li H, Jiang X, et al. ALOX5-mediated ferroptosis acts as a distinct cell death pathway upon oxidative stress in Huntington's disease. Genes & Development. 2023;37(5-6):204-217. doi:10.1101/gad.350211.122
BibTeX
@article{Song2023,
author = {Song, Shujuan and Su, Zhenyi and Kon, Ning and Chu, Bo and Li, Huan and Jiang, Xuejun and Luo, Jianyuan and Stockwell, Brent R and Gu, Wei},
title = {ALOX5-mediated ferroptosis acts as a distinct cell death pathway upon oxidative stress in Huntington's disease},
journal = {Genes & Development},
year = {2023},
volume = {37},
number = {5-6},
pages = {204--217},
doi = {10.1101/gad.350211.122}
}
EUVIMED